In addition, other anti-PD-L1 antibodies including BMS-936559 are in multiple clinical trials for the treatment of NSCLC, renal cell cancer, head and neck cancer, gastric cancer, and other cancers24–27. The gene discussed is CD274; the disease is non-small cell lung carcinoma.